Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy

References

• Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003;46:3–19.
   PubMed Web of Science ®Google Scholar
• Garg SK. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. Diabetes Technol Ther 2010;12:11–24.
   PubMed Web of Science ®Google Scholar
• Cohen A, Horton ES. Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control. Curr Med Res Opin 2007;23:905–17.
   PubMed Web of Science ®Google Scholar
• Ali MK, Bullard KM, Gregg EW. Achievement of goals in U.S. Diabetes Care, 1999-2010. N Engl J Med 2013;369:287–8.
   PubMed Web of Science ®Google Scholar
• Owens DR, Monnier L, Bolli GB. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus. Diabetes Metab 2013;39:485–96.
   PubMed Web of Science ®Google Scholar
• Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S. Incretins: their physiology and application in the treatment of diabetes mellitus. Diabetes Metab Res Rev 2014;30:354–71.
   PubMed Web of Science ®Google Scholar
• Göke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995;7:2294–300.
   PubMed Web of Science ®Google Scholar
• Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515–20.
   PubMed Web of Science ®Google Scholar
• Wang Q, Chen K, Liu R, et al. Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. PLoS One 2010;5:e12734.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). Exenatide, FDA label. 2009. Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf. Last accessed 14 September, 2015.
   Google Scholar
• US Food and Drug Administration (FDA). Liraglutide, FDA label. 2010. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022341lbl.pdf. Last accessed 14 September, 2015.
   Google Scholar
• US Food and Drug Administration (FDA). Exenatide extended-release, FDA label. 2012. Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022200s000lbl.pdf. Last accessed 14 September, 2015.
   Google Scholar
• Poole RM, Nowlan ML. Albiglutide: first global approval. Drugs 2014;74:929–38.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). Albiglutide, FDA label. 2014. Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125431s000lbl.pdf. Last accessed 14 September, 2015.
   Google Scholar
• Bolli GB, Munteanu M, Dotsenko S, Niemoeller E, Boka G, Wu Y, Hanefeld M. Efficacy and safety of lixisenatide once daily vs placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med 2014;31:176–84.
   PubMed Web of Science ®Google Scholar
• Samson SL, Garber A. GLP-1R agonist therapy for diabetes: benefits and potential risks. Curr Opin Endocrinol Diabetes Obes 2013;20:87–97.
   PubMed Web of Science ®Google Scholar
• Petrie JR. The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc Diabetol 2013;12:130.
   PubMed Web of Science ®Google Scholar
• Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther 2012;30:e146–55.
   PubMed Web of Science ®Google Scholar
• Sanofi. ELIXA press release. Sanofi announces top-line results for cardiovascular outcomes study of Lyxumia® (lixisenatide). 2015. Available from http://en.sanofi.com/NasdaQ_OMX/local/press_releases/sanofi_announces_topline_resul_1904474_19-03-2015!07_00_00.aspx. Last accessed 14 September, 2015.
   Google Scholar
• Umapathysivam MM, Lee MY, Jones KL, Annink CE, Cousins CE, Trahair LG, et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes 2014;63:785–90.
   PubMed Web of Science ®Google Scholar
• Werner U. Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying–preclinical evidence. J Diabetes Complications 2014;28:110–14.
   PubMed Web of Science ®Google Scholar
• Ahrén B, Gautier JF, Berria R, Stager W, Aronson R, Bailey CJ. Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014;16:861–8.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140–9.
   PubMed Web of Science ®Google Scholar
• Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015. Endocr Pract 2015;21:413–37.
   PubMed Web of Science ®Google Scholar
• Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268–78.
   PubMed Web of Science ®Google Scholar
• Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84–90.
   PubMed Web of Science ®Google Scholar
• Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473–81.
   PubMed Web of Science ®Google Scholar
• Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224–30.
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52:2046–55.
   PubMed Web of Science ®Google Scholar
• Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39–47.
   PubMed Web of Science ®Google Scholar
• Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33:1255–61.
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh B, Yan P, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431–9.
   PubMed Web of Science ®Google Scholar
• Diamant M, Van Gaal L, Guerci B, Stranks S, Han J, Malloy J, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol 2014;2:464–73.
   PubMed Web of Science ®Google Scholar
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:728–42.
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, González JG, Chan M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012;35:252–8.
   PubMed Web of Science ®Google Scholar
• Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301–10.
   PubMed Web of Science ®Google Scholar
• Buse JB, Nauck M, Forst T, Sheu WH, Shenouda SK, Heilmann CR, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2013;381:117–24.
   PubMed Web of Science ®Google Scholar
• Reusch J, Stewart MW, Perkins CM, Cirkel DT, Ye J, Perry CR, et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. Diabetes Obes Metab 2014;16:1257–64.
   PubMed Web of Science ®Google Scholar
• Nauck M, Stewart M, Perkins C. HARMONY 2 wk 52 results: albiglutide monotherapy in drug naïve patients with type 2 diabetes mellitus [abstract 55-LB]. Diabetes 2013;62:LB15.
   Google Scholar
• Ahrén B, Johnson SJ, Stewart M, Cirkel DT, Yang F, Perry C, et al. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care 2014;37:2141–8.
   PubMed Web of Science ®Google Scholar
• Weissman PN, Carr MC, Ye J, Cirkel DT, Stewart M, Perry C, Pratley R. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia 2014;57:2475–84.
   PubMed Web of Science ®Google Scholar
• Home PD, Shamanna P, Stewart M, Yang F, Miller M, Perry C, Carr MC. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1-year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes Obes Metab 2015;17:179–87.
   PubMed Web of Science ®Google Scholar
• Home P, Stewart M, Mallory J, Miller DM, Perry CR, Carr MC. Harmony 5 Year 3 results: albiglutide vs. placebo and vs. pioglitazone in triple therapy (background metformin and glimepiride) in people with type 2 diabetes [abstract 963-P]. Diabetes 2014;63:A247.
   Web of Science ®Google Scholar
• Rosenstock J, Fonseca VA, Gross JL, Ratner RE, Ahrén B, Chow FC, et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care 2014;37:2317–25.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, Harman-Boehm I, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2014;2:289–97.
   PubMed Web of Science ®Google Scholar
• Leiter LA, Carr MC, Stewart M, Jones-Leone A, Scott R, Yang F, Handelsman Y. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care 2014;37:2723–30.
   PubMed Web of Science ®Google Scholar
• Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 2014;37:2159–67.
   PubMed Web of Science ®Google Scholar
• Giorgino F, Benroubi M, Sun J-H, Zimmermann AG, Pechtner V. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care 2015. [Epub ahead of print.]
   PubMed Web of Science ®Google Scholar
• Umpierrez G, Tofé Povedano S, Pérez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 2014;37:2168–76.
   PubMed Web of Science ®Google Scholar
• Blonde L, Jendle J, Gross J, Woo V, Jiang H, Fahrbach JL, Milicevic Z. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet 2015;385:2057–66.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide vs. sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014;37:2149–58.
   PubMed Web of Science ®Google Scholar
• Dungan KM, Povedano ST, Forst T, González JG, Atisso C, Sealls W, Fahrbach JL. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014;384:1349–57.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092–100.
   PubMed Web of Science ®Google Scholar
• Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Exenatide-113 Clinical Study Group Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628–35.
   Google Scholar
• Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083–91.
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther 2010;12:233–40.
   PubMed Web of Science ®Google Scholar
• Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian RM, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009;32:762–8.
   PubMed Web of Science ®Google Scholar
• Mathieu C, Ostenson CG, Matthaei S, Reaney M, Krarup T, Guerci B, et al. Using exenatide twice daily or insulin in clinical practice: results from CHOICE. Diabetes Ther 2013;4:285–308.
   PubMed Web of Science ®Google Scholar
• Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE; EFC6018 GetGoal-Mono Study Investigators. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012;35:1225–31.
   PubMed Web of Science ®Google Scholar
• Ahrén B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 2013;36:2543–50.
   PubMed Web of Science ®Google Scholar
• Yu Pan C, Han P, Liu X, Yan S, Feng P, Zhou Z, et al. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia). Diabetes Metab Res Rev 2014;30:726–35.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Hanefeld M, Shamanna P, Min KW, Boka G, Miossec P, et al. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). J Diabetes Complications 2014;28:386–92.
   PubMed Web of Science ®Google Scholar
• Pinget M, Goldenberg R, Niemoeller E, Muehlen-Bartmer I, Guo H, Aronson R. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab 2013;15:1000–7.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Raccah D, Korányi L, Maffei L, Boka G, Miossec P, Gerich JE. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care 2013;36:2945–51.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Aronson R, Home P, Marre M, Niemoeller E, Miossec P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013;36:2489–96.
   PubMed Web of Science ®Google Scholar
• Seino Y, Min KW, Niemoeller E, Takami A; EFC10887 GETGOAL-L Asia Study Investigators. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 2012;14:910–17.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Forst T, Aronson R, Sauque-Reyna L, Souhami E, Silvestre L, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care 2013;36:2497–503.
   PubMed Web of Science ®Google Scholar
• Cho YM, Wideman RD, Kieffer TJ. Clinical application of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. Endocrinol Metab (Seoul) 2013;28:262–74.
   PubMedGoogle Scholar
• Petersen AB, Knop FK, Christensen M. Lixisenatide for the treatment of type 2 diabetes. Drugs Today (Barc) 2013;49:537–53.
   PubMed Web of Science ®Google Scholar
• Bond A. Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus. Proc (Bayl Univ Med Cent) 2006;19:281–4.
   PubMedGoogle Scholar
• Davies M, Aktin S, Bain SC, Scott D, Rossing P, Shamkhalova M, et al. Efficacy and safety of liraglutide vs. placebo as add-on to existing diabetes medication in subjects with type 2 diabetes (T2DM) and moderate renal impairment (LIRA-RENAL) [abstract 965-P]. Diabetes 2014;63:A247–8.
   Web of Science ®Google Scholar
• Scheen AJ. GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician? Ann Endocrinol (Paris) 2013;74:515–22.
   PubMed Web of Science ®Google Scholar
• Kapitza C, Forst T, Coester HV, Poitiers F, Ruus P, Hincelin-Méry A. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab 2013;15:642–9.
   PubMed Web of Science ®Google Scholar
• Meier JJ, Rosenstock J, Hincelin-Méry A, Roy-Duval C, Delfolie A, Coester HV, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care 2015;38:1263–73.
   PubMed Web of Science ®Google Scholar
• Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care 2011;34:2508–14.
   PubMed Web of Science ®Google Scholar
• Monnier L. Comment on: Riddle et al. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care 2012;35:e2.
   PubMedGoogle Scholar
• Egan JM, Meneilly GS, Elahi D. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am J Physiol Endocrinol Metab 2003;284:E1072–9.
   PubMed Web of Science ®Google Scholar
• Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26:2370–7.
   PubMed Web of Science ®Google Scholar
• Pinkney J, Fox T, Ranganath L. Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide. Ther Clin Risk Manag 2010;6:401–11.
   PubMed Web of Science ®Google Scholar
• Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008;30:1448–60.
   PubMed Web of Science ®Google Scholar
• Robinson LE, Holt TA, Rees K, Randeva HS, O’Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013;3:e001986.
   PubMed Web of Science ®Google Scholar
• Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011;10:22.
   PubMed Web of Science ®Google Scholar
• Wang F. Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials [Abstract 124-LB]. Diabetes 2015;64:LB32.
   Google Scholar
• Linnebjerg H, Seger M, Kothare P, Hunt TC, Mitchell MI. The effect of exenatide on QTc interval in healthy subjects. Diabetes 2009;58:abstract 597-P.
   Web of Science ®Google Scholar
• Ahrén B, Vorokhobina N, Souhami E, Demil N, Ye J, Aronson R. Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day. J Diabetes Complications 2014;28:735–41.
   PubMed Web of Science ®Google Scholar
• Nauck M, Azar ST, Blonde L, Dicker D, Puig-Domingo M, Nikonova E, et al. Relationship between changes in postprandial glucagon, patient characteristics, and response to lixisenatide as add-on to oral antidiabetics [abstract 971-P]. Diabetes 2014;63:A249.
   Web of Science ®Google Scholar
• Gómez-Huelgas R, Ambos A, Arteaga JM, Leiter LA, Marchesini G, Nikonova E, et al. Lixisenatide is effective and well tolerated in patients with type 2 diabetes mellitus and renal impairment [abstract 992-P]. Diabetes 2014;63:A254–5.
   Web of Science ®Google Scholar
• Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med 2010;27:1024–32.
   PubMed Web of Science ®Google Scholar
• Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992;267:7402–5.
   PubMed Web of Science ®Google Scholar
• Hare KJ, Knop FK. Incretin-based therapy and type 2 diabetes. Vitam Horm 2010;84:389–413.
   PubMed Web of Science ®Google Scholar
• Thorens B, Porret A, Bühler L, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993;42:1678–82.
   PubMed Web of Science ®Google Scholar
• Wysham C, Bergenstal R, Malloy J, Yan P, Walsh B, Malone J, Taylor K. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med 2011;28:705–14.
   PubMed Web of Science ®Google Scholar
• Trautmann M, Van Gaal L, Han J, Hardy E. Three-year efficacy and safety of exenatide once weekly: a pooled analysis of 3 trials [Abstract 1120-P]. Diabetes 2015;64:A287.
   Web of Science ®Google Scholar
• Rendell M, Perkins C, Scott RA. Harmony 2 Year 3 results: albiglutide monotherapy in drug-naïve patients with T2DM [abstract 959-P]. Diabetes 2014;63:A245–6.
   Web of Science ®Google Scholar
• Bode BW, Stewart M, Cirkel D, Cirkel DT, Ye J, Perry CR, et al. Harmony 1 Year 3 results: albiglutide vs. placebo in patients with type 2 diabetes mellitus not controlled on pioglitazone (Pio) ± metformin (Met) [abstract 960-P]. Diabetes 2014;63:A246.
   Web of Science ®Google Scholar
• Weissman P, Stewart M, Cirkel D, Ye J, Ambery P. Harmony 4: 3-year efficacy of albiglutide (Albi) vs. insulin glargine (Glar) in patients with T2DM [abstract 961-P]. Diabetes 2014;63:A246.
   Web of Science ®Google Scholar
• Glaesner W, Vick AM, Millican R, Ellis B, Tschang SH, Tian Y, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev 2010;26:287–96.
   PubMed Web of Science ®Google Scholar
• Ferdinand KC, White WB, Calhoun DA, Lonn EM, Sager PT, Brunelle R, et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension 2014;64:731–7.
   PubMed Web of Science ®Google Scholar
• Ferdinand KC, Sager PT, Atisso CM, Butro FT. Once-weekly dulaglutide does not increase the risk for CV events in type 2 diabetes: a prespecified CV meta-analysis of prospectively adjudicated CV events [Abstract 1127-P]. Diabetes 2015;64:A289.
   Web of Science ®Google Scholar
• Seino Y, Nakajima H, Miyahara H, Kurita T, Bush MA, Yang F, Stewart MW. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Curr Med Res Opin 2009;25:3049–57.
   PubMed Web of Science ®Google Scholar
• Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ3rd; EGO Study Group. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab 2011;13:418–25.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. 2011 guideline for management of postmeal glucose in diabetes. Available from http://www.idf.org/sites/default/files/postmeal%20glucose%20guidelines.pdf. Last accessed 14 September, 2015.
   Google Scholar
• DeVries JH, Bain SC, Rodbard HW, Seufert J, D’Alessio D, Thomsen AB, et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care 2012;35:1446–54.
   PubMed Web of Science ®Google Scholar
• Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154:103–12.
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005–12.
   PubMed Web of Science ®Google Scholar
• Arnolds S, Dellweg S, Clair J, Dain MP, Nauck MA, Rave K, Kapitza C. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 2010;33:1509–15.
   PubMed Web of Science ®Google Scholar
• Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 2009;31:1511–23.
   PubMed Web of Science ®Google Scholar
• Sheffield CA, Kane MP, Busch RS, Bakst G, Abelseth JM, Hamilton RA. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 2008;14:285–92.
   PubMedGoogle Scholar
• Davidson J, Stager W, Paranjape S, Berria R, Leiter LA. Achieving postprandial glucose control with lixisenatide (LIXI) improves glycemic control in T2DM patients (pts) on basal insulin [Abstract 1160-P]. Diabetes 2015;64:A299.
   PubMed Web of Science ®Google Scholar
• Ahmann A, Rodbard HW, Rosenstock J, Lahtela JT, de Loredo L, Tornøe K, Boopalan A, et al.A, on behalf of the NN2211-3917 Study Group. Efficacy and safety of liraglutide vs. placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2015. [Epub ahead of print.]
   PubMed Web of Science ®Google Scholar
• Merchante AA, Casan R, Abellán P, Sanz J, Fabra A, Sánchez C. Liraglutide added to insulin: beyond the intensification of basal insulin [Abstract 1156-P]. Diabetes 2015;64:A298.
   Web of Science ®Google Scholar
• Raccah D, Lin J, Wang E, Germé M, Perfetti R, Bonadonna RC, et al. Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials. J Diabetes Complications 2014;28:40–4.
   PubMed Web of Science ®Google Scholar
• Hirsch IB, Schneider D, King A, Polonsky WH, Reid TS, Shubrook J, et al. A short-acting GLP-1 analog or prandial insulin to supplement basal insulin?–Moving toward personalized management of type 2 diabetes mellitus. Postgrad Med 2014;126:135–44.
   PubMed Web of Science ®Google Scholar
• Diamant M, Nauck MA, Shaginian R, Malone JK, Cleall S, Reaney M, et al. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 2014;37:2763–73.
   PubMed Web of Science ®Google Scholar
• Shao N, Kuang HY, Hao M, Gao XY, Lin WJ, Zou W. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. Diabetes Metab Res Rev 2014;30:521–9.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Hanefeld M, Gentile S, Aronson R, Tinahones FJ, Guerci B, et al., on behalf of the GetGoal-Duo2 study investigators. Advancing basal insulin glargine with prandial lixisenatide QD vs insulin glulisine QD or TID in T2DM: the GetGoal-Duo2 evidence-based trial (NCT01768559) [Abstract 107-LB]. Diabetes 2015;64:LB27.
   Google Scholar
• Mathieu C, Rodbard HW, Cariou B, Handelsman Y, Philis-Tsimikas A, Ocampo Francisco AM, et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab 2014;16:636–44.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Fonseca V. Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse! Diabetes Care 2007;30:2972–3.
   PubMed Web of Science ®Google Scholar